AXT (NASDAQ:AXTI) CEO Morris Young Sells 73,897 Shares

AXT Inc (NASDAQ:AXTI) CEO Morris Young sold 73,897 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $112.39, for a total value of $8,305,283.83. Following the completion of the sale, the chief executive officer owned 2,261,328 shares in the company, valued at $254,150,653.92. The trade was a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

AXT Stock Down 3.7%

Shares of NASDAQ AXTI opened at $106.70 on Thursday. AXT Inc has a fifty-two week low of $1.67 and a fifty-two week high of $143.16. The firm’s 50-day simple moving average is $88.03 and its 200 day simple moving average is $46.15. The stock has a market cap of $6.98 billion, a P/E ratio of -344.18 and a beta of 1.80.

AXT (NASDAQ:AXTI) last issued its quarterly earnings data on Thursday, April 30th. The semiconductor company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. AXT had a negative net margin of 14.69% and a negative return on equity of 5.71%. The business had revenue of $26.92 million for the quarter, compared to analysts’ expectations of $26.22 million. AXT has set its Q2 2026 guidance at 0.060-0.080 EPS. On average, sell-side analysts anticipate that AXT Inc will post 0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on AXTI shares. Wedbush boosted their price target on shares of AXT from $8.50 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Weiss Ratings raised AXT from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. B. Riley Financial upped their price target on AXT to $21.00 and gave the stock a “neutral” rating in a report on Friday, February 20th. Northland Securities set a $125.00 price target on AXT in a report on Wednesday. Finally, UBS Group set a $35.00 target price on AXT in a research note on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $43.80.

Hedge Funds Weigh In On AXT

Several hedge funds have recently added to or reduced their stakes in AXTI. CloudAlpha Capital Management Limited Hong Kong bought a new position in AXT during the fourth quarter worth about $22,738,000. Maytree Asset Management Ltd bought a new stake in AXT in the 4th quarter valued at approximately $11,156,000. Destination Wealth Management bought a new stake in AXT in the 3rd quarter valued at approximately $458,000. Penn Capital Management Company LLC acquired a new position in shares of AXT during the 3rd quarter worth approximately $729,000. Finally, Allworth Financial LP increased its position in shares of AXT by 3,764.7% during the 4th quarter. Allworth Financial LP now owns 11,594 shares of the semiconductor company’s stock worth $190,000 after purchasing an additional 11,294 shares during the last quarter. Institutional investors own 49.52% of the company’s stock.

About AXT

AXT, Inc (NASDAQ: AXTI) is a global supplier of compound and single-element semiconductor substrates, offering a range of materials critical for high-performance electronic and optoelectronic devices. Founded in 1986 and headquartered in Fremont, California, AXT specializes in the development, manufacture and distribution of wafers composed of gallium arsenide (GaAs), indium phosphide (InP), gallium nitride (GaN) and other compound semiconductor materials. These substrates serve as the foundational platforms for devices used in data communications, wireless infrastructure, advanced computing, consumer electronics and photovoltaic applications.

AXT’s product portfolio encompasses a variety of wafer sizes, dopant concentrations and crystal orientations, tailored to meet the precise specifications of its customers.